DiaSys Corporation Announces the Introduction of new FDA and CE Marked ELISA Product Line.WATERBURY, Conn. -- DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ) a global healthcare products company announced today the introduction of a new line of 47 ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent. ELISA n. products of which 18 are now FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved and CE marked. The Company will sell the 18 FDA approved tests in the United States and the 18 CE marked tests in Europe. DiaSys Corporation will sell the entire line of 47 tests in the international market. Product descriptions can be accessed on the DiaSys Corporation website at DiaSys.com. The ELISA products now offered by DiaSys Corporation to be sold in the United States and in Europe through our wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , DiaSys Europe consist of Tumor Markers Tumor Markers Definition Tumor markers are measurable biochemicals that are associated with a malignancy. They are either produced by tumor cells (tumor-derived) or by the body in response to tumor cells (tumor-associated). , Cardiac Markers, Steroid, Anemia, Fertility Hormones, Growth Hormone, Allergy and Thyroid tests. The ELISA products to be sold by DiaSys Corporation to the international market will also include Cardiac Markers, Tumor Markers, Infectious Diseases, Thyroid, Steroids and Down Syndrome in addition to those that are CE marked and approved by the FDA. DiaSys Corporation will continue to add new ELISA and Rapid Test products in the United States and Europe as they are approved by the FDA and CE marked. DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion